Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

Company Overview

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors. Both programs leverage the company’s proprietary immune activator to induce rapid cytokine release and recruitment of innate and adaptive immune cells at the tumor site. Preclinical studies have also demonstrated potential for a systemically delivered candidate under investigation for metastatic solid tumors. In addition, Calidi maintains a pipeline of preclinical programs exploring prophylactic and therapeutic applications against viral pathogens.

Headquartered in South San Francisco, California, Calidi Biotherapeutics was founded to advance synthetic RNA-based immunomodulators into the clinic and is led by a management team with extensive experience in immuno-oncology drug development. The company collaborates with academic partners and contract manufacturing organizations to support clinical and regulatory activities. Calidi Biotherapeutics is publicly traded on the New York Stock Exchange under the symbol CLDI.

Key Stats

• Today's Range: $1.51 to $1.59
• 50-Day Range: $1.45 to $7.25
• 52-Week Range: $1.41 to $46.68
• Volume: 150,369 shs
• Average Volume: 576,800 shs
• Market Capitalization: $5.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Calidi Biotherapeutics Stock Analysis - MarketRank™

Calidi Biotherapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Calidi Biotherapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share.

Price to Book Value per Share Ratio

Calidi Biotherapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.74% of the float of Calidi Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Calidi Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Calidi Biotherapeutics has recently decreased by 21.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Calidi Biotherapeutics does not currently pay a dividend.

Dividend Growth

Calidi Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.74% of the float of Calidi Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Calidi Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Calidi Biotherapeutics has recently decreased by 21.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for CLDI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

2 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Calidi Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $455,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Calidi Biotherapeutics is held by insiders.

Percentage Held by Institutions

Only 12.53% of the stock of Calidi Biotherapeutics is held by institutions.

CLDI Stock Analysis - Frequently Asked Questions

How have CLDI shares performed this year?

Calidi Biotherapeutics' stock was trading at $13.80 at the beginning of the year. Since then, CLDI stock has decreased by 88.8% and is now trading at $1.5450.

How were Calidi Biotherapeutics' earnings last quarter?

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) issued its earnings results on Tuesday, November, 12th. The company reported ($7.80) EPS for the quarter, topping analysts' consensus estimates of ($10.20) by $2.40.

When did Calidi Biotherapeutics' stock split?

Calidi Biotherapeutics shares reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Calidi Biotherapeutics?

Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:CLDI
• Previous Symbol: NYSE:CLDI
• CIK: 1855485
• Web: calidibio.com
• Phone: 858-794-9600
• Fax: N/A
• Employees: 38
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,152.88%
• Return on Assets: -175.92%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 1.13
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: $50 thousand
• Price / Sales: 105.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 3,430,000
• Free Float: 3,196,000
• Market Cap: $5.30 million
• Optionable: N/A
• Beta: 1.07